Does diminished neurogenesis contribute to AD onset/progression or merely correlate with disease?

OPEN

The authors explicitly state this contribution is still debated despite evidence that both glucocorticoids and cytokines inhibit hippocampal neurogenesis. Resolving causality versus correlation is critical for therapeutic targeting. Gap type: open_question Source paper: Depression as a risk factor for Alzheimer's disease: Genes, steroids, cytokines and neurogenesis - What do we need to know? (2016, Frontiers in neuroendocrinology, PMID:26746105)

Priority: 0.80 Domain: neurogenesis Hypotheses: 0
📊 Landscape Analysis

Landscape Summary: Does diminished neurogenesis contribute to AD onset/progression or merely correlate with disease? is a 0.8 priority gap in neurogenesis. It has 0 linked hypotheses with average composite score 0.000. Status: open.

Key Unanswered Questions

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

Does diminished neurogenesis contribute to AD onset/progression or merely correlate with disease? — INVOKE-2 (completed)

📈 Living Dashboards
0
Hypotheses
0.000
Top Score
0.000
Avg Score
0
Debates
0.00
Avg Quality
0%
Resolution
0
Mechanistic Families
Gap Resolution Progress0%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

associated with (21)

entities-atp7b-geneADentities-rosADentities-histone-methylationADTAUADTDP-43AD
▸ Show 16 more

biomarker for (1)

tau cleavage productsAD

causes (6)

ADneurodegenerationPHOSPHORYLATED_TAUADBETA_AMYLOIDADADmemory_lossADIMMUNE_TOL
▸ Show 1 more

contributes to (1)

NEUROINFLAMMATIONAD

cross disease mechanism in (5)

MAPTADTREM2ADNLRP3ADPINK1ADGRNAD

depleted in (1)

SPM_levelsAD

prevents (1)

NAD+ augmentationAD

protective against (1)

cognitive stimulationAD

regulates (1)

ADPROTEOME

risk factor for (4)

genetically at-risk individualsADAPOE ε4ADmicroglial primingADAPOE4AD

targets (1)

resveratrolAD

therapeutic target for (6)

CCR2ADTREM2ADSaracatinibADanti-amyloid antibodiesADNAD+ augmentationAD
▸ Show 1 more

treats (1)

HTL9936AD
🕑 Activity Feed

No activity recorded yet.

💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

  • Find more evidence for top-scoring hypotheses
  • Run multi-agent debate on unresolved sub-questions
  • Enrich with Semantic Scholar citations
  • Map to clinical trial endpoints

← Back to All Gaps